According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7 trillion in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity.
Escalating health care costs are also bound to be of major concern to Astiva Health and other providers of health insurance policies as they navigate the financial implications of this trend. The surge in spending highlights the ongoing challenges in managing health care affordability in the United States, where expenditures have consistently outpaced economic growth.
The CMS actuaries' report underscores the significant impact of pharmaceutical costs on overall health care spending. GLP-1 receptor agonists, originally developed for type 2 diabetes, have gained popularity for weight management, leading to increased utilization and higher costs. This class of drugs includes well-known brands such as Ozempic and Wegovy, which have seen soaring demand.
For health insurers, the rising cost of these medications translates into higher premiums and increased financial pressure. Companies like Astiva Health must adapt their coverage policies and pricing strategies to manage the risk while ensuring access to necessary treatments. The broader implications include potential shifts in employer-sponsored insurance plans and government programs like Medicare and Medicaid.
The data also reflects a broader trend of health care spending consuming a larger share of the U.S. economy. In 2025, health care expenditures accounted for nearly 20% of GDP, up from previous years. This trend raises questions about sustainability and the need for systemic reforms to control costs without compromising quality.
As the debate over health care reform continues, the CMS data provides critical insights for policymakers, providers, and payers. The focus on GLP-1 drugs as a cost driver may prompt discussions about drug pricing regulations, formulary management, and value-based care models. For now, the 7% growth rate signals that health care inflation remains a persistent challenge, demanding innovative solutions from all stakeholders.
